Anderem A and Ulevitch RJ. (2001). Toll-like receptors in the induction of the innate immune response. Nature, 406: 782-7.
Babineau T, Hackford A, Kenler A, Bistrian B, Forse A, Fairchild PG, Heard S, Keroack M., Caushaj P and Benotti P. (1994a). A phase II multicenter, double-blind, randomized, placebo-controlled study of three dosages of an immunomodulator (PGG-Glucan) in high-risk surgical patients. Archives of Surgery, 129, pp. 1204-1210.
Babineau TJ, Marcello P, Swails W, Kenler A., Bistrian B and Forse A. (1994b). Randomized phase I/II trial of a macrophage-specific immunomodulator (PGG-Glucan) in high-risk surgical patients. Annals of Surgery, 220, pp. 601-609.
Basset C, Holton J, O’Mahony R and Roitt I. (2003). Innate immunity and pathogen-host interaction. Vaccine, 1;21 Suppl 2:S12-23.
Bell S, Goldman VM, Bistrian BR, Arnold AH, Ostroff G and Forse RA. (1999). Effect of beta-glucan from oats and yeast on serum lipids. Critical Review in Food Science & Nutrition, 39, pp. 189-202.
Beyan H, Buckley LR, Yousaf N, Londei M and Leslie RD. A role for innate immunity in type 1 diabetes? (2003). Diabetes Metab Res Rev., 19(2):89-100. Review.
Bohn JA and BeMiller JN. (1995). (1-3)-beta-D-glucans as biological response modifiers: a review of structure-function relationships. Carbohydrate Polymers, 28, pp. 3-14.
Browder W, Williams D, Pretus H, Oliver G, Enrichens F, Mao P and Franchello A. (1990) Beneficial effect of enhanced macrophage function in the trauma patient. Annals of Surgery, 211, pp. 605-12.
Brown GD and Gordon S. (2001). Immune recognition A new receptor for beta-glucans. Nature, 413, pp. 36-37.
Cheung NK, V Modak S, Vickers A and Knuckles B. (2002). Orally administered B-glucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunol Immunother. 51: 557-564.
Davidson MH, Dugan LD, Burns JH, Bova J, Story K and Drennan KB. (1991). The hypocholesterolemic effects of beta-glucan in oatmeal and oat bran. A dose-controlled study. JAMA. 265: 1833-1839.
Decuypere J, Dierick N and Boddez S. (1998. The potentials for immunostimulatory substances (beta-1,3/1,6 glucans) in pig nutrition. Journal of Animal and Feed Sciences, 7, pp. 259-265.
Delatte SJ, Evans J, Hebra A, Adamson W, Othersen HB and Tagge EP. (2001). Effectiveness of beta-glucan collagen for treatment of partial-thickness burns in children. J Pediatr.Surg., 36, pp. 113-118.
Dellinger EP, Babineau TJ, Bleicher P, Kaiser AB, Seibert GB, Postier RG, Vogel SB, Norman J, Kaufman D, Galandiuk S and Condon RE. (1999.) Effect of PGG-glucan on the rate of serious postoperative infection or death observed after high-risk gastrointestinal operations. Betafectin Gastrointestinal Study Group. Arch.Surg., 134, pp. 977-983.
Di Luzio NR, Williams DL, McNamee RB and Malseth VG. (1980). Comparative evaluation of the tumor inhibitory and antibacterial activity of solubilized and particulate glucan. Recent Results Cancer Res., 75, pp. 165-172.
Dritz SS, Shi J, Kielian TL, Goodband RD, Nelssen JL and Tokach MD. (1995). Influence of dietary beta-glucan on growth performance, nonspecific immunity, and resistance to Streptococcus suis infection in weanling pigs. J Anim Sci ,73: 3341-50.
Engstad R and Raa J. Immune-stimulation improving health and performance. Feed Magazine (Kraftfutter), 7-8, 261-266. 1999.
Engstad RE and Robertsen B. (1993). Recognition of yeast cell wall glucan by Atlantic salmon (Salmon salar L.) macrophages. Developmental and Comparative Immunology 17: 319-330.
Engstad RE and Robertsen B. (1994). Specificity of a β-glucan receptor on macrophages from Atlantic salmon (Salmon salar L.). Journal of Biotechnology, 3: 203-207.
Engstad RE and Robertsen B. (1994). Specificity of a beta-glucan receptor on macrophages from Atlantic salmon (Salmo salar L.). Developmental and Comparative Immunology, 18, pp. 397-408.
Engstad RE and Robertsen B. (1995). Effect of structurally different beta-glucans on immune responses in Atlantic salmon (Salmo salar L.). Journal of Marine Biotechnology, 3, pp. 203-207.
Felippe JD, Rocha E Silva MD, Maciel FMB, Macedo Soares AD and Mendes NF. (1993). Infection prevention in patients with severe multiple trauma with the immunomodulator beta 1-3 polyglucose (glucan). Surgery, Gynecology & Obstetrics, 177, pp. 383-387.
Ganz T and Lehrer RI. (2001). Antimicrobial peptides in innate immunity. I: Development of novel antimicrobial agents: Emerging strategies (Karl Lohner, editor). Horizen Scientific Press, Norfolk, 139-47.
Goldman RC. (1995). Biological response modification by beta-D-glucans. Annual Reports in Medicinal Chemistry, 30, pp. 129-138.
Gura T. Innate immunity. Ancient system gets new respect. Science, 2001; 291: 2068-71.
Hancock REW and Scott MG. (2000). The role of antimicrobial peptides in animal defenses. PNAS, 97: 8856-8861.
Hofer M, Pospisil M, Viklicka S, Pipalova I, Hola J, Netikova J and Sandula J. (1995). Effects of postirradiation carboxymethylglucan administration in mice. Int. J.Immunopharmacol., 17, pp. 167-174.
Jong SC and Birmingham JM. (1993). Medicinal and therapeutic value of the Shiitake mushroom. Adv Appl Microbiol, 39: 153-84.
Kaneko Y and Chihara G. (1992). Potentiation of host resistance against microbial infections by lentinan and its related polysaccharides. I: Friedman H, Klein TW, Yamaguchi H. (red). Microbial infections: Role of biological response modifiers. Plenum Press, New York, 201-15.
Konopski Z, Rasmussen LT, Seljelid R and Eskeland T. (1991). Phagocytosis of beta-1,3-D-glucan-derivatized microbeads by mouse peritoneal macrophages involves three different receptors. Scandinavian Journal of Immunology, 33, pp. 297-306.
Levy JA. The importance of the innate immune system in controlling HIV infection and disease. Trends Immunol, 2001; 22: 312-6.
Libby P and Ridker PM. (1999). Novel inflammatory markers of coronary risk. Circulation, 100: 1148-1150.
Lolis E and Bucala R. (2003). Therapeutic approaches to innate immunity: severe sepsis and septic shock. Nat Rev Drug Discov.; 2(8):635-45.
Maeda YY, Yonekawa H and Chihara G. (1994). Application of lentinan as cytokine inducer and host defense potentiator in immunotherapy of infectious diseases. I: Masihi N (red) Immunotherapy of infections, Marcel Dekker, New York, 261-79.
Matsuo T, Arika T, Mitani M and Komatsu N. (1982). Pharmacological and Toxicological studies of a new antitumor polysaccharide, Schizophyllan. Arzneimmittelforschung, 32, pp. 647-656.
Medzhitov R. (2001). CpG-DNA: a security code for host defense. Nature Immunol, 2: 15-16.
Moriyuki H and Ichimura M. (1980). [Acute toxicity of lentinan in mice and rats (author’s transl)]. J. Toxicol. Sci., 5 Suppl, pp. 1-9.
Müller A, Raptis J, Rice PJ, Kalbfleisch JH, Stout RD, Ensley HE, Browder W and Williams DL. (2000). The influence of glucan polymer structure and solution conformation on binding to (1–>3)-beta-D-glucan receptors in a human monocyte-like cell line. Glycobiology, 10, pp. 339-346.
Nagler-Anderson C. Man the barrier! (2001). Strategic defenses in the intestinal mucosa. Nature Reviews, Immunology, 1: 59-67.
Noda K, Takeuchi S, Yajima A, Akiya K, Kasamatsu T, Tomoda Y, Ozawa M, Sekiba K, Sugimori H and Hashimoto S. (1992). Clinical effect of sizofiran combined with irradiation in cervical cancer patients: a randomized controlled study. Cooperative Study Group on SPG for Gynecological Cancer. Jpn. J. Clin. Oncol., 22, pp. 17-25.
Ozinsky A, Underhill M, Fontenot JD, Hajjar AM, Smith KD, Wilson CB, Schroeder L and Aderem A. (2000). The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors [In Process Citation]. Proc. Natl. Acad. Sci. U.S.A, 97, pp. 13766-13771.
Portera CA, Love EJ, Memore L, Zhang L, Müller A, Browder W et al. (1997). Effect of macrophage stimulation on collagen biosynthesis in the healing wound. Amer Surg, 63: 125-31.
Poutsiaka DD, Mengozzi M, Vannier E, Sinha B and Dinarello CA. (1993). Cross-linking of the beta-glucan receptor on human monocytes results in interleukin-1 receptor antagonist but not interleukin-1 production. Blood, 82, pp. 3695-3700.
Pretus HA, Ensley HE, McNamee RB, Jones EL, Browdner WI. and Williams DL. (1991). Isolation, physiochemical characterisation and preclinical efficacy evaluation of soluble scleroglucan. The Journal of Pharmacology and Experimental Therapeutics, 257, pp. 500-510.
Raa J. (1996). The use of immunostimulatory substances in fish and shellfish farming. Reviews in Fisheries Science, 4 (3): 229-288.
Raa J et al.(2002). United States Patent Application Publication. No.: US 2002/0009463 A1. Novel, non-antigenic, mucosal adjuvavant formulation which enhances the effects of substances, including vaccine antigens, in contact with mucosal body surfaces.
Robertsen B, Rørstad G, Engstad R and Raa J. (1990). Enhancement of non-specific disease resistance in Atlantic salmon, Salmo salar L., by a glucan from Saccharomyces cerevisiae cell walls. Journal of Fish Diseases, 13: 391-400.
Rook GAW and Stanford JL. Give us this day our daily germs. Immunol Today, 1998; 19: 113-6.
Rylander R and Holt PG. (1998). (1-3)-beta-D-Glucan and endotoxin modulate immune response to inhaled antigen. Mediators of Inflammation, 7: 105-10.
Sartor RB. (2003). Innate immunity in the pathogenesis and therapy of IBD. J Gastroenterol, 38 Suppl 15: 43-7. Review.
Seljelid R, Gao Q, Berge A and Ugelstad J. (1997). Biological effects of the immunomodulator beta-1,3-D-polyglucose are strongly potentiated by conjugation to biodegradable microbeads. Scand J Immunol, 45: 683-7.
Seljelid R. (1989). Tumor regression after treatment with aminated beta-1,3-D-polyglucose is initiated by circulatory failure. Scand J Imunol, 29: 181-92.
Seljelid R, Bøgwald J and Lundwall Å. (1981). Glycan stimulation of macrophages in vitro. Experimental Cell Research, 131: 121-129.
Seljelid R. (1986) A water soluble aminated beta-1,3-D-glucose derivative caused regression of solid tumors in mice. Bioscience Reports, 6, pp. 845-852.
Seljelid R, Rasmussen LT, Larm O and Hoffmann J. The protective effect of beta-1,3-D-glucan derivatized plastic beads against Escherichia coli infection in mice. Scand J Immunol, 1987; 25: 55-60.
Sfondrini L, Balsari A and Menard S. (2003). Innate immunity in breast carcinoma. Endocr Relat Cancer, 10 (2): 301-8. Review.
Soltys J and Quinn MT. (1999). Modulation of endotoxin- and enterotoxin-induced cytokine release by in vivo treatment with beta-(1,6)-branched beta-(1,3)-glucan. Infection Immunity, 67: 244-252.
Suzuki T, Ohno N, Ohshima Y and Yadomae T. (1998). Soluble mannan and beta-glucan inhibit the uptake of Malassezia furfur by human monocytic cell line, THP-1. FEMS Immunology and Medical Microbiology, 21: 223-230.
Sveinbjørnsson B, Rushfeldt R, Seljelid R and Smedsrød B. (1998). Inhibition of establishment and growth of mouse liver metastases after treatment with interferon gamma and beta-1,3-D-glucan. Hepatology, 27: 1241-8.
Takahashi H, Ohno N, Adachi Y and Yadomae T. (2001). Association of immunological disorders in lethal side effect of NSAIDs on beta-glucan-administered mice. FEMS Immunol. Med. Microbiol., 1313, pp. 1-12.
Tsukada C, Yokoyama H, Miyaji C, Ishimoto Y, Kawamura H and Abo T. (2003). Immunopotentiation of intraepithelial lymphocytes in the intestine by oral administrations of beta-glucan. Cell Immunol, 221: 1-5.
Vereschagin EI, Lambalgen AAv, Dushkin MI, Schwartz YS, Polyakov L, Heemskerk A, et al. (1998). Soluble glucan protects against endotoxin shock in the rat: the role of the scavenger receptor. Shock, 9:193-8.
Wakimoto H, Johnson PR, Knipe DM and Chiocca EA. (2003). Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells. Gene The., 10 (11): 983-90. Review.
Williams DL, Mueller A and Browder W. (1995). Preclinical and clinical evaluation of carbohydrate immunopharmaceuticals in the prevention of sepsis and septic sequelae. Journal of Endotoxin Research, 2: 203-8.
Williams DL, Mueller A and Browder W. (1998). Glucan-based macrophage stimulators: a review of their anti-infective potential. Clin Immunotherapy, 5: 392-9.
Williams DL. (1997). Overview of (1-3)-beta-D-glucan immunobiology. Mediators of Inflammation, 6, pp. 247-250.
Williams DL, Mueller A and Browder W. (1996). Glucan-based macrophage stimulators – A review of their anti-infective potential. Clinical Immunotherapy, 5, pp. 392-399.
Williams DL, Pretus HA, McNamee RB, Jones EL, Ensley HE and Browder IW. (1992). Development of a water-soluble, sulfated (1-3)-beta-D-glucan biological response modifier derived from Saccharomyces cerevisiae. Carbohydrate Research, 235, pp. 247-257.
Xia Y, Vetvicka V, Yan J, Hanikýrová M, Mayadas T and Ross GD. (1999). The beta-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. Journal of Immunology, 162 pp. 2281-2290.
Yoshioka S, Ohno N, Mioura T, Adachi Y and Yadomae T. (1998). Immunotoxicity of soluble beta-glucans induced by indomethacin treatment. Fems Immunology And Medical Microbiology, 21, pp. 171-179.
Zülli F, Suter F, Blitz H and Nissen HP. (1997). CM-glucan: A biological response modifier from Baker´s yeast for skin care. SÖFW-Journal, 123, pp. 535-541.